RxDoctor Payments DataLook up a doctor →

Lisa Abbott, MD

Endocrinology, Diabetes & Metabolism · Reno, NVNPI 1609883701

Payments from drug & device makers

$1,239,047in general payments, 2019–2025

Across 1,243 payments — averaging $996.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ascendis Pharma Endocrinology Inc$444K
  • AbbVie$260K
  • AstraZeneca$234K
  • Takeda Pharmaceuticals U.S.A., Inc.$122K
  • Eli Lilly$86K
  • Shire North American Group Inc$28K
  • plus $64K from 54 others
$45,249in research payments, 2019–2025

Across 30 payments — averaging $1508.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Shire North American Group Inc$26K
  • Eli Lilly$9K
  • Takeda Pharmaceuticals U.S.A., Inc.$7K
  • AbbVie$3K
  • Corcept Therapeutics$156

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Ascendis Pharma Endocrinology Inc294$444,276
AbbVie51$260,046
AstraZeneca(2 entities)50$234,262
Takeda Pharmaceuticals U.S.A., Inc.31$122,166
Eli Lilly6$86,188
Shire North American Group Inc22$28,364
Novo Nordisk AS44$21,962
Novo Nordisk45$7,342
Corcept Therapeutics64$5,389
Clarus Therapeutics Inc.7$4,635
Amgen(2 entities)79$2,878
Johnson & Johnson9$2,428
Senseonics, Incorporated7$2,170
Lilly USA, LLC69$2,037
Mannkind Corporation62$1,651
Vertex3$1,200
Amarin Pharma, Inc.48$983
Xeris Pharmaceuticals, Inc.36$932
Medtronic(2 entities)30$905
Sanofi-aventis U.S. LLC35$899
Insulet Corporation21$831
Bayer18$822
Boehringer Ingelheim26$669
Recordati_rare_diseases_inc.14$639
Radius Health, Inc.23$564
Antares Pharma, Inc.18$390
Abbott19$389
Neurocrine Biosciences, Inc.4$359
Dexcom, Inc.6$335
Tandem Diabetes Care, Inc.6$283
Ascensia Diabetes Care US Inc.5$266
Chiesi USA, Inc.7$260
GRT US Holding, Inc.6$215
IBSA Pharma Inc.12$210
Lexicon Pharmaceuticals, Inc.2$173
Companion Medical, Inc.4$163
Amryt Pharma Holdings Ltd2$154
Valeritas, Inc.3$138
Gilead1$124
Merck7$123
Soleno Therapeutics, Inc.1$119
Almatica Pharma LLC5$117
Biomarin Pharmaceutical Inc.2$111
Astellas Pharma US Inc4$108
Kyowa Kirin, Inc.4$85
Madrigal Pharmaceuticals2$68
Zealand Pharma US, Inc.3$66
Verity Pharmaceuticals Inc.2$47
Regeneron Healthcare Solutions, Inc.3$46
Ferring Pharmaceuticals Inc.2$42
Eisai Inc.2$39
Alfasigma USA, Inc.2$35
Rhythm Pharmaceuticals, Inc.1$33
Halozyme Inc1$28
Janssen Scientific Affairs, LLC1$27
Alnylam Pharmaceuticals Inc.1$27
Alvogen Inc1$26
BETA Bionics, Inc.1$24
Endo Pharmaceuticals Inc.1$23
Pfizer1$23

How this compares

$1,239,047 in reported general payments places this provider in the 95th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.

See all endocrinology, diabetes & metabolism providers in Nevada →

Medicare billing

Part B allowed, 2024
$233,777
Medicare patients
454
Services billed
6,697

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Reno

See the full list for Nevada →

Where these figures come from

Is this you, or does something look wrong? →